Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 5, 2011, Pages

  Sheng, Xiaoyan ^a   Wang, Min ^a   Lu, Meng ^a   Xi, Beili ^b   Sheng, Hongguang ^b   Zang, Ying Qin ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

Author keywords

GATA binding protein 3; Liver X receptor; Signal transducer and activator of transcription; Sterol regulatory element binding protein 1c; T box expressed in T cells

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; LIVER X RECEPTOR; LUCIFERASE; RHEIN; STAT6 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENERGY BALANCE; ENERGY EXPENDITURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FOOD INTAKE; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; IMMUNOMODULATION; INSULIN RESISTANCE; LIPID DIET; LIPOGENESIS; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TH1 CELL; TH2 CELL; WESTERN BLOTTING;

ADIPOSITY; ANIMALS; ANTHRAQUINONES; BLOOD GLUCOSE; BODY WEIGHT; CELL LINE; CHEMOKINES; CYTOKINES; DIET; ENERGY METABOLISM; ENZYME INHIBITORS; FATTY LIVER; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; LIPIDS; LIPOGENESIS; LIVER; LUCIFERASES; MICE; MICE, INBRED C57BL; OBESITY; ORPHAN NUCLEAR RECEPTORS; OXYGEN CONSUMPTION; TRANSFECTION;

EID: 79955566362     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00332.2010     Document Type: Article

References (39)

1. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22: 1129-1133, 2005.
2. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 35: 531-537, 2001.
3. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 54: 1314-1323, 2005.
4. Brandt KD, Smith G, Kang SY, Myers S, O'Connor B, Albrecht M. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage 5: 438-449, 1997.
5. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152, 2004.
6. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42: 987-1000, 2005.
7. Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR. The protein kinase IKK3 regulates energy balance in obese mice. Cell 138: 961-975, 2009.
8. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35: 373-379, 2002.
9. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297: 240-243, 2002.
10. Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81: 243-248, 2004.
11. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998.
12. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 31: 633-640, 2000.
13. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27: 609-630, 2007.
14. Jay H, Jennifer H, Nicole R. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol 15: 699-704, 2002.
15. Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Exp Clin Endocrinol Diabetes 115: 571-576, 2007.
16. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, McClain CJ. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46: 823-830, 2007.
17. Kalaany NY, Gauthier KC, Zavacki AM, Mammen PA, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ. LXRs regulate the balance between fat storage and oxidation. Cell Metab 1: 231-244, 2005.
18. Kremer M, Hines IN, Milton RJ, Wheeler MD. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology 44: 216-227, 2006.
19. Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH. The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 27: 173-193, 2007.
20. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 8: 549-558, viii-ix, 2004.
21. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48: 670-678, 2008.
22. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner Rde L. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol 8: 782-791, 2008.
23. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923, 2003.
24. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16: 421-427, 2005.
25. Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46: 1519-1529, 2007.
26. Mendes AF, Caramona MM, de Carvalho AP, Lopes MC. Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol Toxicol 91: 22-28, 2002.
27. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37: 1202-1219, 2003.
28. Patrick B, Geoffrey W, David B. Role of primary intrahepatic T-cell activation in the "liver tolerance effect." Immunol Cell Biol 80: 84-92, 2002.
29. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693-704, 1998.
30. Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, Martel-Pelletier J. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol 28: 814-824, 2001.
31. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev 14: 2831-2838, 2000.
32. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274: 30028-30032, 1999.
33. Steffensen KR, Gustafsson JA. Putative Metabolic Effects of the Liver X Receptor (LXR). Diabetes 53: S1, 2004.
34. Sujong K, Insuk S, Joon-Ik A, Ki-Hwan L, Yeon Sook L, Yong Sung L. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 340: 99-109, 2004.
35. Taccoen A, Berdah L. [Diacetylrhein, a new therapeutic approach of osteoarthritis]. Rev Rhum Ed Fr 60: 83S-86S, 1993.
36. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55: 415-424, 2006.
37. Vito R, Barbara R. The liver as an immunological organ. Hepatology 43: S54-S62, 2006.
38. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53, Suppl 3: S215-S219, 2004.
39. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277: 19353-19357, 2002.